Abbreviations huhepc, human hepcidin encoded by HAMP gene with an extra N-terminal methionine; m1hepc, mouse hepcidin encoded by Hepc1 gene with an extra N-terminal methionine; MES, 2N-m
Trang 1hepcidin, the iron-regulatory hormone
Bruno Gagliardo1, Audrey Faye2,3, Maryse Jaouen1, Jean-Christophe Deschemin2,3, Franc¸ois
Canonne-Hergaux4, Sophie Vaulont2,3and Marie-Agne`s Sari1
1 CNRS (UMR 8601), Universite´ Paris Descartes, France
2 Institut Cochin CNRS (UMR 8104), Universite´ Paris Descartes, France
3 Inserm (U567), Universite´ Paris Descartes, France
4 CNRS (ICSN), Gif-Sur-Yvette, France
Hepcidin is a 25 amino acid, cysteine-rich peptide, first
identified in human blood [1] and urine [2] as an
anti-microbial peptide of the defensin family Human
hep-cidin is the product of the HAMP gene, which encodes
an 84 amino acid precursor protein [3,4] In addition,
hepcidin genes have also been identified in several
species, including the mouse [5], rat [6], pig [7], dog [8]
and fish [9–11] In mammals, the hepcidin gene is
expressed predominantly in hepatocytes and constitutes
the master regulator of iron homeostasis Hepcidin
gene expression is positively regulated by iron and
inflammation and negatively regulated by anemia and
hypoxia [5,12] There is compelling evidence that
dysregulation of hepcidin underlies many iron disorders
Most of the iron overload syndromes (primary hemo-chromatosis and secondary iron overloads) imply a reduction of hepcidin secretion whereas, in contrast, overexpression of hepcidin appears to play a deter-mining role in anemia of inflammation or inflammation
of chronic disease [13] and iron-refractory iron deficiency anemia [14]
HAMP and Hepc1 encode precursors of 84 and 83 amino acids, respectively, which contain typical 24 and
23 amino acid endoplasmic reticulum targeting signal motifs at the N-terminus of the human and mouse precursors, respectively This signal is cleaved to produce prohepcidin, harboring a 35 amino acid proregion and the C-terminus 25 amino acid mature
Keywords
antimicrobial peptide; Escherichia coli
expression; ferroportin; hepcidin; iron
homeostasis
Correspondence
M.-A Sari, UMR 8601, Universite´ Paris
Descartes, 45 rue des Saints-Pe`res, 75006
Paris, France
Fax: +33 1428 68387
Tel: +33 1428 62142
E-mail: marie-agnes.sari@univ-paris5.fr
(Received 1 April 2008, revised 22 May
2008, accepted 28 May 2008)
doi:10.1111/j.1742-4658.2008.06525.x
Hepcidin is a liver produced cysteine-rich peptide hormone that acts as the central regulator of body iron metabolism Hepcidin is synthesized under the form of a precursor, prohepcidin, which is processed to produce the biologically active mature 25 amino acid peptide This peptide is secreted and acts by controlling the concentration of the membrane iron exporter ferroportin on intestinal enterocytes and macrophages Hepcidin binds to ferroportin, inducing its internalization and degradation, thus regulating the export of iron from cells to plasma The aim of the present study was
to develop a novel method to produce human and mouse recombinant hep-cidins, and to compare their biological activity towards their natural recep-tor ferroportin Hepcidins were expressed in Escherichia coli as thioredoxin fusion proteins The corresponding peptides, purified after cleavage from thioredoxin, were properly folded and contained the expected four-disulfide bridges without the need of any renaturation or oxidation steps Human and mouse hepcidins were found to be biologically active, promoting ferro-portin degradation in macrophages Importantly, biologically inactive aggregated forms of hepcidin were observed depending on purification and storage conditions, but such forms were unrelated to disulfide bridge formation
Abbreviations
huhepc, human hepcidin encoded by HAMP gene with an extra N-terminal methionine; m1hepc, mouse hepcidin encoded by Hepc1 gene with an extra N-terminal methionine; MES, 2(N-morpholino)ethanesulfonic acid; SELDI-TOF, surface enhanced laser desorption ionization time of flight; TFA, trifluroacetic acid; TRX, thioredoxin.
Trang 2peptide This prohepcidin is further processed through a
furin-type propeptide cleavage site to generate the
secreted 25 amino acid hepcidin [2,15] The 25 amino
acid peptide forms a hairpin loop stabilized by four
disulfide bonds, one of which is an unusual vicinal bond
between adjacent cysteines at the hairpin turn [16] A
recent structure⁄ function study revealed that the
N-terminus of hepcidin is essential for its bioactivity, and
that the structure is otherwise permissive for changes [17]
Once in the circulation, the peptide acts to limit
gastrointestinal iron absorption and serum iron levels
by inhibiting dietary intestinal iron absorption and
iron recycling by the macrophages [18] This is
achieved by hepcidin binding to ferroportin, the
trans-membrane iron transporter necessary for iron transfer
out of intestinal epithelial cells and macrophages [19],
resulting in its internalization and subsequent
degrada-tion [20,21]
Although the functional role of hepcidin in iron
metabolism has been well documented, little is known
concerning its cell biology Chemical synthesis of
human hepcidin has been successful but difficult to
achieve [22–24] due to folding restrictions imposed by
the four-disulfide bridges [10,16] Other studies have
reported the purification of human recombinant
hepci-din in the form of fusion proteins [25–28] and, until
very recently [29], none of the recombinant hepcidins
were shown to be bioactive in iron metabolism
In the present study, we describe an efficient
proce-dure for purification of biologically active recombinant
hepcidins This constitutes an important step that will
allow for a better understanding of hepcidin biology,
which is a prerequisite for the use of hepcidin in
medi-cal applications
Results
Strategies for hepcidin expression and nomenclature
We were able to produce properly folded recombinant hepcidins with the correct four-disulfide bridges with-out the need of a denaturation⁄ renaturation step A Novagen pET32-LIC vector expression system was used into which the hepcidin encoding sequence was cloned downstream of a thioredoxin (TRX) sequence
to produce a fusion protein under the control of a T7 promoter TRX was chosen as the fusion protein because it is involved in disulfide bridge formation [30,31] A double tag system links TRX and hepcidin: a his-tag upstream of a thrombin cleavage site and a S-tag upstream of an enterokinase cleavage site (Fig 1) Noteworthy, the recombinant hepcidin produced after cleavage exhibited an extra methionine at the N-termi-nus compared to the native peptide, as a result of the nature of the enterokinase cleavage site (Table 1) The major expected characteristics of the cleaved pro-teins⁄ peptides are presented in Fig 1, together with the nomenclature used in the present study
Origami B cells were chosen as a host strain because they carry mutations both in TRX and glutathione reductase genes, hence increasing cytosolic formation
of disulfide bridges compared to those obtained in the highly reductive environment of a regular Escherichia coli strain This strain choice was indeed important because mouse hepcidin encoded by Hepc1 gene with
an extra N-terminal methionine (m1hepc) purified from a BL21(DE3) strain was found mostly as an insoluble multimer peptide (data not shown)
Fig 1 Scheme of hepcidin production and their expected characteristics The name of each construct used through the study is given next
to its corresponding cartoon, together with the amino acid numbers (AA), isoelectric point and the theoretical average and monoisotopic (in parenthesis) mass obtained using Protein Parameter software (ExPasy; http://www.expasy.org/cgi-bin/protparam) Yields are expressed in % (nmol of purified protein X100 per nmol of TRX-hepc) and are representative of three independent preparations.
Trang 3Plasmid construction
Cloning of m1hepc and human hepcidin encoded by
HAMP gene with an extra N-terminal methionine
(huhepc) was performed using synthetic
oligonucleo-tides Complementary hepcidin oligonucleotides were
annealed and directly cloned into the pET32LIC vector
(Table 1) Upon transformation and amplification in
E coli TG1 cells, m1hepc and
pET32LIC-huhepc vectors were purified, checked by sequencing
and used to transform Origami B cells
Fusion protein expression
TRX-hepcidin 20 kDa fusion proteins (TRX-m1hepc
and TRX-huhepc) were produced under the same
conditions Therefore, only TRX-huhepc production is
described here Transformed pET32LIC-huhepc
Origami cells were cultured in high density ZYM-5052
medium at 25C, as described previously [32], except
that the autoinduction lactose step was replaced by a
‘classical’ isopropyl thio-b-d-galactoside induction step
after 30 h of growth (see Experimental procedures)
The decrease of temperature from 37C to 25 C was
found necessary to avoid the formation of inclusion
bodies because TRX-huhepc found in these structures
was highly aggregated and very difficult to recover
Human hepcidin purification
Hepcidin purification was carried out in three steps:
(a) TRX-huhepc purification; (b) thrombin cleavage of
TRX-huhepc to generate S-huhepc; and (c) S-huhepc
enterokinase digestion to generate huhepc For
unknown reasons, huhepc (as well as TRX-m1hepc) appeared to be resistant to enterokinase digestion, avoiding a direct purification of huhepc from TRX-huhepc The purification was followed by SDS⁄ PAGE, for proteins or peptides, and also ExperionTMcapillary electrophoresis for proteins
Step1: purification of TRX-huhepc After 30 h of growth, 3 h of induction and lysis, 8.5 g
of soluble proteins were obtained; 8% of which com-prised TRX-huhepc (approximately 700 mg) (Fig 2, lane 2) Some TRX-huhepc remained in the insoluble fraction (Fig 2, lane 1) and could not be recovered, even in the presence of urea or guanidine (data not shown) Lowering the temperature to 15C did not enhance the yield of soluble fusion protein To enrich the fusion protein in the soluble fraction, a 65C heat-ing step was performed (Fig 2, lane 3) This step allowed most of the unwanted proteins to be irrevers-ibly precipitated because 500 mg of soluble proteins were present in the heated supernatant; 70% of which comprised TRX-huhepc (350 mg) Even though 50%
of the fusion protein was lost in this process, this step, which takes advantage of the heat resistance of TRX [33], was found to be necessary to obtain pure TRX-huhepc
The TRX-huhepc enriched solution was purified to homogeneity using affinity TALON Co2+ chroma-tography, with the remaining unwanted proteins flowing through the column (Fig 2, lane 4) and TRX-huhepc being eluted with 150 mm imidazole followed by 2(N-morpholino)ethanesulfonic acid (MES) buffer (pH 5) (Fig 2, lane 5), and found to be
Table 1 Primers used for hepcidin cloning and PCR, and primary structure of the purified peptides and proteins Forward and reverse oligonucleotides encoding hepcidin sequence contained 5¢ and 3¢ additional nucleotides (in bold) corresponding to the LIC sequence of pET-32Ek ⁄ LIC vector.
Sequence (5¢- to 3¢) Primers
TAAATGCTGTAACAATTCCCAGTGTGGTATCTGTTGCAAAACATAA
GTTACAGCATTTACAGCAGAAGATGCAGATGGGGAAGTTGGTGTCCA
CGGCTGCTGTCATCGATCAAAGTGTGGGATGTGCTGCAAGACGTAA
ATGACAGCAGCCGCAGCAGAAAATGCAGATCGGGAAGTGGGTGTCCA Proteins
Trang 4at least 90% pure as measured on the Experion
device Routinely, 3.5 mg of fusion protein was
obtained from 1 g of cell pellet
Step 2: thrombin cleavage
After elution, TRX-huhepc was digested for 16 h with
1 U of thrombin per 10 mg of protein, yielding an
almost complete cleavage (Fig 2, lane 6) S-huhepc
generated by thrombin digestion was separated away
from TRX using an HPLC purification step on a C18
semi-preparative column The purified S-huhepc
(Fig 2, lane 7) was lyophilized to dryness, resuspended
at 1 mgÆmL)1 in enterokinase cleavage buffer and
treated for 6 h with 10 U of enterokinase per mg of
S-huhepc Low temperature was avoided to minimize
peptide precipitation during cleavage Finally,
purifica-tion of huhepc was achieved by anion exchange
chro-matography As previously noticed for S-huhepc,
huhepc had a propensity to aggregate but remained
soluble in the presence of salts Thus, the enterokinase
cleaved mixture was simply diluted in one volume of
water to adjust the NaCl concentration to below
40 mm Under these conditions, low salt buffer at
pH 7, huhepc flowed through the UnoQ anion
exchange column (Fig 2, lane 8), whereas the other
peptides (S and eventually S-huhepc) bound to the
column Again, to avoid irreversible aggregation of
huhepc, the huhepc solution was directly lyophilized in the presence of buffer to maintain further solubility of the peptide The peptide was stored as a dry lyophilized powder until used When required, remaining salts were withdrawn either upon thorough dialysis (using
1000 Da molecular weight cut-off dialysis tubing) or HPLC chromatography (Fig 3) or size exclusion chromatography using bio-gel P4 resin (Bio-Rad, Marnes-la-Coquette, France) Routinely, 2 mg of pure huhepc was obtained from 60 g of Origami cells
Mouse hepcidin purification Mouse hepcidin (m1hepc) was obtained as described for huhepc, except for minor modifications related to differences in the pI of the peptide (Fig 1) Entero-kinase digestion was carried out at pH 6.2 (instead of
pH 7 for m1hepc) and the UnoQ chromatography step was run at pH 6.2 rather than pH 7 The production yield of m1hepc was slightly lower than that of huhepc (8% instead of 13%, respectively, starting form
Fig 3 HPLC profile of pure recombinant (A) mouse or (B) human hepcidins (A) Fifty microlitres of huhepc (0.1 mgÆmL)1) was injected on a MOS C8 and (B) 50 lL of m1hepc (0.01 mgÆmL)1) was injected on a Vydac C18 column using a stepwise acetonitrile gradient.
Fig 2 Purification of huhepc followed by SDS ⁄ PAGE using 12%
Bis-Tris Criterion XT gels in the absence of reducing agent Large
(left) and small (right) molecular weight markers (Bio-Rad) are
indi-cated in kDa Lane 1, 200 lg of crude extract of TRX-huhepc
expressing cells; lane 2, 150 lg of TRX-huhepc expressing cells
cytosolic fraction (prior heating step); lane 3, 50 lg cleared
cyto-solic fraction after removal of the heat denaturated proteins; lane 4,
30 lg of Co 2+ Talon unbound protein fraction; lane 5, 50 lg of
Co2+Talon 150 m M imidazole eluted fraction, containing
TRX-hu-hepc; lane 6, 40 lg of TRX-huhepc thrombin cleavage mixture;
lane 7, 6 lg of HPLC purified S-huhepc; lane 8, 3 lg of UnoQ
purified huhepc (lyophilized in the presence of buffer) *TRX-huhepc
dimer formed upon disulfide bridge between two thioredoxin
subunits.
Trang 5TRX-hepc), most likely due to the higher propensity
of m1hepc to precipitate during the enterokinase
cleavage step
Characterization of the recombinant proteins
and peptides
Purity of the recombinant proteins was assessed by
SDS⁄ PAGE or Experion capillary electrophoresis,
HPLC chromatography and MS As shown in Fig 2,
the peptides and proteins appeared fairly clean by
SDS⁄ PAGE analysis (in the absence of reducing agent)
and, importantly, ran at the expected molecular
weights: TRX-huhepc at 20 kDa (Fig 2, lane 5);
S-hu-hepc at 6 kDa (Fig 2, lane 7); and huS-hu-hepc appears to
run as a 3.5 kDa peptide (Fig 2, lane 8) The extra
sharp band marked with an asterisk, at approximately
37 kDa, corresponded to TRX-huhepc dimers due to
disulfide bridges between two TRX domains This band
was indeed absent when the SDS⁄ PAGE was run in the
presence of reducing agents (data not shown) Purified
hepcidin remained soluble and largely as a monomer
after the anion exchange chromatography or when
resuspended in the presence of buffer after
lyophiliza-tion (Fig 2, lane 8) C18 HPLC analysis also displayed
a single peak for each peptide (Fig 3, m1hepc and
huhepc), when assessing the purity of the samples
Interestingly, desalted hepcidins, either obtained
after HPLC purification or desalted after anion
exchange chromatography following dialysis or
exclu-sion chromatography, always aggregated over time
This phenomenon was observed with low salt
solu-tions, regardless of whether the hepcidins were stored
at 4C or at)80 C and in the presence or absence of
glycerol or detergents These polymeric hepcidin forms
could not be reverted to the monomer forms, even in
the presence of reducing agents such as dithiothreitol
or tris(2-carboxyethyl)phosphine (data not shown)
Therefore, pure hepcidins were routinely lyophilized
immediately after the anion exchange chromatography
and kept as a salt containing powder To quantify the hepcidin content in the lyophilized powder, a sample was injected on a Vydac (Grace, Templemars, France) C18 HPLC column, lyophilized again and weighed Concentration was also confirmed using UV-visible measurements [2]
To verify that all the cysteines were engaged in disul-fide bridges, Ellman’s reagent was used to measure the content of free cysteines [34] As indicated in Table 2, S-m1hepc and S-huhepc, m1hepc and huhepc contained less than one free cysteine per monomer, indicating that
at least 90% of the hepcidins and hepcidin derivatives contained the expected four-disulfide bridges
Finally, the presence of the four-disulfide bridges was also confirmed using ESI MS (Table 2) for S-m1hepc and S-huhepc Upon deconvulation, the molecular weight was 6020.6 ±1 Da for S-m1hepc and 6057.4 ± 1 Da for S-huhepc, with both values being
in good agreement with the theoretical mass of 6020.82 Da and 6055.94 Da expected for the corre-sponding S-hepcidins containing four-disulfide bridges Unfortunately, ESI MS on pure hepcidins was impos-sible due to the difficulty of ionizing the peptide Therefore, surface enhanced laser desorption ionization time of flight (SELDI-TOF) MS, previously described
as a powerful technique to analyze hepcidin, was used [35] Clean mass spectra were observed when peptides were run on regular (NP20) protein chips (Table 2) The calculated mass was 2885.2 ± 1 Da for m1hepc and 2920.3 ± 1 Da for huhepc, with both values being
in good agreement with the theoretical values of 2885.49 Da and 2920.60 Da, respectively, expected for fully oxidized disulfide bridged forms, demonstrating that the recombinant hepcidins were pure and con-tained four-disulfide bridges Interestingly, SELDI-TOF MS performed on aggregated hepcidins (Fig 4B) gave values identical to those of the non-aggregated form, indicating that the polymeric bands observed by SDS⁄ PAGE analysis were not related to interchain disulfide bridges but simple aggregation
Table 2 Characterization of purified hepcidin derivatives The calculated average molecular weight was obtained either using ESI MS or SELDI-TOF MS, as described in the Experimental procedures ND, not determined; ), no activity detected or no m ⁄ z signal obtained; +, activity measured: at least 10 mm diameter growth inhibition of E coli in plate assay using 100 pmol of each peptide, complete disappear-ance of ferroportin signal at the membrane of iron treated macrophage J774 cells in the presence of 700 l M of each of the hepcidin deriva-tives Free SH content is related to the lack of detection of free thiols using Ellman’s reagent All data were obtained for two independent preparations of hepcidin (MS and SH contents) and three independent preparations for activity measurements.
Trang 6Compared activities of hepcidins and S-hepcidins
The antibacterial activity of m1hepc, huhepc and their
S-tag forms (S-m1hepc and S-huhepc) was tested
against E coli using a plate assay [27] In our
condi-tions, 10 lL of a 10 lm solution for either of the four
peptides routinely resulted in a 10 mm diameter
growth inhibition of E coli whereas 10 lL of buffer or
medium resulted in no more than a 3 mm diameter
growth inhibition (Table 2) These results demonstrate
that recombinant hepcidins displayed obvious
antibac-terial activity against E coli and that similar activity
was observed for the S-hepcidins compared to that of
the corresponding hepcidins
The iron-related bioactivity of the recombinant
pro-teins was tested in Fe-NTA treated J774 macrophages
for their potential to degrade the hepcidin receptor,
ferroportin As shown by western blotting (Fig 5),
only iron treated macrophage cells express detectable
amount of membrane bound ferroportin (Fig 5, lane 1
versus lane 2) As a control, the human synthetic 25
amino acid mature peptide (Peptides International,
Louisville, KY, USA) was used at 700 nm for 5 h As
expected, a complete disappearance of ferroportin was
observed (Fig 5, lane 3) When tested under the same
conditions, the huhepc also provoked a complete
dis-appearance of ferroportin (Fig 5, lane 8) By contrast,
the S-hepcidins were completely inactive towards
ferro-portin degradation (Fig 5, lanes 4 and 5) These
results were obtained routinely when ‘monomer’ forms
of hepcidin were used in the assay Interestingly, when
salt-free hepcidins were used (Fig 5, lanes 6 and 7), no
effect was observed on ferroportin degradation,
sug-gesting that the salt-free hepcidin forms have lost their
biological activity
The inactivation of hepcidin activity in salt free solu-tion was further investigated A fracsolu-tion of active UnoQ purified human hepcidin was desalted using a P4 exclusion chromatography, concentrated, and com-pared with its parent ‘salted’ hepcidin The ‘salt-free’ hepcidin form was found completely inactive towards
Fig 4 (A) Analysis by SDS ⁄ PAGE of UnoQ purified huhepc before or after ‘desalting’ using a P4 exclusion column settled in water and concentrated by lyophilization (B) SELDI-TOF spectrum of desalted hepcidin This result is representative of three differ-ent experimdiffer-ents performed with external or internal calibration using low mass peptide standards (Sigma, St Louis, MO, USA).
Fig 5 Effects of hepcidin treatment on ferroportin expression in J774 cells Expression of ferroportin was studied in macrophage J774 cells treated with Fe-NTA for 16 h and with the indicated hep-cidin or S-tagged hephep-cidin for 5 h Membrane proteins (30 lg per lane) were separated by SDS ⁄ PAGE, electro-transferred onto nitro-cellulose and analyzed with anti-ferroportin serum The ponceau red staining of the membrane is shown Lane 1 is the control without Fe-NTA and lanes 2 to 8 correspond to samples treated with Fe-NTA Lane 3, 700 n M huhepc from Peptides International; lanes
4 and 5, 100 and 700 n M of enterokinase digested mixture of S-m1hepc; lanes 6 and 7, 100 and 700 n M of pure ‘desalted’ huhepc; lane 8, UnoQ purified salt-containing huhepc (700 n M ).
Trang 7ferroportin Interestingly, the migration profile by
SDS⁄ PAGE of this inactive form of hepcidin showed
an important proportion of multimers (Fig 4A)
Fur-thermore, the polymerization pattern was identical in
the absence or presence of a reducing agent (not
shown) Altogether, these results clearly demonstrate
that human hepcidin aggregates in the absence of salt,
that this aggregation is not related to intermolecular
disulfide bridge formation (Fig 4B) and, more
impor-tantly, that human hepcidin activity is significantly
reduced upon aggregation
Recombinant m1hepc was also shown to degrade
ferroportin, although less efficiently than huhepc At
100 nm, although both huhepc and synthetic hepcidin
(Peptides International) induced a complete
disappear-ance of ferroportin from the macrophage membranes,
m1hepc yielded only a 50% decrease of ferroportin
under the same conditions Finally,
aggregation-induced loss of hepcidin activity was also observed
with the m1hepc, to a larger extent than the human
form, most likely due to its slightly more hydrophobic
nature (human hepcidin contains two histidine and one
arginine residues instead of three asparagine residues
for the mouse form)
Discussion
The TRX fusion protein approach in association with
the use of the Origami strain was found to be ideal
for the expression of hepcidins The recombinant
hep-cidin peptides, containing eight cysteines engaged in
four intramolecular disulfide bridges, were properly
folded, fully oxidized and biologically active
Further-more, the need of denaturation–renaturation or
reduction–oxidation steps (often present in other
pro-tocols of hepcidin preparation, either recombinant
[26–28] or synthetic [10,17,23]) were removed By
con-trast to another report [26], our recombinant products
were apparently metal-free The human and mouse1
hepcidins were purified by two cleavage steps:
removal of TRX with thrombin and S-tagging with
enterokinase The recombinant products differed from
the native hepcidins by the presence of an extra
amino acid (methionine) at the N-terminus However,
this extra amino acid did not appear to affect the
biological activities of the recombinant products
because their activities were found comparable to that
of a commercially available synthetic 25 amino acid
human hepcidin (Peptides International) This is in
agreement with observations of Nemeth et al [17],
who showed that a human hepcidin of 26 amino
acids, bearing an extra alanine in the N-terminal
posi-tion, retained its activity
Interestingly, S-hepcidins, which bear 29 extra amino acids upstream of the hepcidin sequence, con-serve an antibacterial activity comparable to that of the corresponding hepcidin but are completely ineffi-cient in degrading the iron exporter ferroportin This result is in accordance with observations of Nemeth
et al [17], who demonstrated that the N-terminal part
of hepcidin was necessary for interaction with ferro-portin, and strongly suggests that the presence of the S-tag prevents the hepcidin-ferroportin interaction It
is thus predictable that any N-terminal tagged recom-binant hepcidin products, such as GST [26], His [28]
or other fusions, could interfere with hepcidin activ-ity Very recently, Koliaraki et al [29] described the production of a C-terminal his-tagged human hepci-din using Pichia pastoris as a host for expression Although it was not possible to express untagged hepcidin, the C-terminal his-tagged recombinant pep-tide that they produced was able to bind ferroportin and promote its degradation in Raw 264.7 macro-phages [29]
The results of the present study also emphasize that the determination of hepcidin antimicrobial properties
is not relevant to assessing hepcidin bioactivity in iron metabolism and that only a measurement of hepcidin activity towards ferroportin degradation and⁄ of cellular iron retention should be considered
In the present study, we have demonstrated that aggregated forms of hepcidins (dimers or tetramers), harboring the same SELDI-TOF mass spectrum as their corresponding monomers, are inactive against ferroportin As previously demonstrated [36], hepci-din derivatives, including the recently described C-terminal his-tagged peptide [29], are very likely to precipitate, yet the aggregation does not involve interchain disulfide bridge formation This aggregation occurs at neutral pH in the absence of salt or upon storage at 4C in solution This phenomenon is likely to explain the poor reproducibility in hepcidin preparation (including commercial preparations) In our hands, the storage of hepcidins as salted lyophi-lized aliquots at )20 C (or less) was found to com-prise the best method for preventing loss of activity over time Reproducible preparation of biologically active hepcidins, either synthetic or recombinant, is a necessary step for investigating the cellular biology
of this hormone and the present study has contrib-uted to this aspect Finally, the strategy described in the present study was also found to be appropriate for the production of prohepcidin (B Gagliardo, personal communication) and may be useful in the preparation of other cysteine rich peptides or proteins
Trang 8Experimental procedures
Bacterial strains, media and chemicals
The TG1 E coli strain [D(lac pro) supE thi hsdD5 F’
traD35 proAB LacIq LacZDM15] was used for cloning and
plasmid DNA purification Origami B(DE3) cells (Novagen,
Merck Chemicals Ltd, Nottingham, UK) [F) ompT hsdSB
(rB ) mB )) gal dcm lacY1 aphC (DE3) gor522::Tn10 trxB
(KanR, TetR)] were used for protein expression
LB [Bacto-tryptone 1% (w⁄ v), yeast extract 0.5% (w ⁄ v),
NaCl 5% (w⁄ v)] and ZYM-5052 [Bacto-tryptone 1% (w ⁄ v),
yeast extract 0.5% (w⁄ v), 25 mm Na2HPO4, 25 mm
KH2PO4, 50 mm NH4Cl, 5 mm Na2SO4supplemented with
2 mm MgSO4, 0.5% glycerol, 0.05% glucose and metal
salts] (1000· metal salts solution: 50 mm FeCl3, 20 mm
CaCl2, 10 mm MnCl2, 10 mm ZnSO4, 2 mm CoCl2, 2 mm
CuCl2, 2 mm NiCl2, 2 mm Na2MoO4, 2 mm Na2SeO3,
2 mm H3BO3, 60 mm HCl) were used as regular and high
density culture media, respectively, in accordance with
Studier et al [32]
Constructions
Human and mouse synthetic oligonucleotides (Table 1)
cor-responding to the hepcidin sequence fused to a LIC site
were synthesized by Eurogentec (Seraing, Belgium)
Mice, unlike humans, have two duplicated genes, Hepc1
and Hepc2 [5,37] Because the mouse Hepc2 gene was found
unrelated to iron metabolism [37,38], Hepc1 was chosen for
the present study
Each primer (10 lm) was annealed to its complementary
partner and heated at 90C Temperature was allowed to
decrease to 25C at 1 CÆmin)1(using a MJ research
ther-mocycler; Bio-Rad) One microlitre of the double stranded
hepcidin DNA was mixed with 1 lL of pET-32Ek⁄ LIC
(50 ng) vector (Novagen) at 25C for 5 min and one-tenth
of the mixture was used to electroporate E coli TG1cells
Upon transformation, colonies were used to prepare
plas-mid DNA and the presence of pET-32Ek⁄ LIC-Hepcidin
vector (either mouse or human) was confirmed by
sequencing performed at Genome Express (Meylan,
France)
Expression
The pET-32Ek⁄ LIC-mouse1hepcidin vector
(pET-32LIC-m1hepc) and the pET-32Ek⁄ LIC-human hepcidin vector
(pET-32LIC-huhepc) were used to transform ORIGAMI
B(DE3) competent cells The transformed cells were
cultured in 50 mL of LB medium supplemented with
kana-mycin (10 mgÆL)1) and ampicillin (50 mgÆL)1) The
precul-ture was used to inoculate 3.6 L of high-density culprecul-ture
medium ZYM-5052 [32] supplemented with kanamycin and
ampicillin The culture was carried out in twelve 2 L Erlen
Flasks at 37C for 3 h, then 20–23 h at 25 C Isopropyl thio-b-d-galactoside (1 mm) was finally added and culture allowed to continue for an extra 3 h at 25C The cells were harvested at 6000 g for 20 min at 4C Routinely, the biomass obtained represented 17 gÆL)1 of wet cells culture
Fusion protein purification
TRX-hepcidin containing cells were resuspended in 5 mL
of phosphate buffer (50 mm Na2HPO4⁄ NaH2PO4) at pH 7 supplemented with NaCl at 300 mmÆg)1of cell pellet Bacte-ria were lysed in the presence of BugBuster (0.5·) lyso-zyme (0.5 gÆL)1) and DNAse (0.05 mgÆg)1 of cell pellet), then sonicated on ice in the presence of phen-ylmethanesulfonyl fluoride (0.5 mm) and the protease inhib-itors leupeptin, pepstatin and aprotinin (10 lgÆmL)1 each) using a Labsonic (B Braun, Melsungen AG, Melsungen, Germany) device operated at 200 W and with a 0.7 s pulse Cells debris were centrifuged at 10 000 g for 20 min The resulting supernatant (15–20 mgÆmL)1 of protein) was heated to 65C and immediately transferred on ice The heat inactivated precipitated proteins were removed by centrifugation at 12 000 g for 15 min and the cleared super-natant, routinely containing 5 mgÆmL)1 of protein, was
St Quentin-en-Yvelines, France) affinity column (15 mL bed volume) The column was washed with five volumes of phosphate buffer and the TRX-Hepcidin fusion protein was eluted with the same buffer completed with imidazole
150 mm (one volume) and 20 mm MES buffer at pH 5 (one volume)
Cleavage and purification of hepcidin
Affinity purified TRX-hepcidin containing fractions were pooled and thoroughly dialyzed at 4C against 20 mm Tris buffer (pH 7.4 at 25C) supplemented with 500 mm NaCl, then 1 unit of biotynilated thrombin (Novagen) was added for 10 mg of fusion protein and cleavage was allowed to proceed for 16 h at room temperature at a protein concen-tration of 1.5–3 mgÆmL)1 The biotynilated thrombin was extracted using sreptavidin-agarose and the resulting solu-tion containing TRX, S-hepcidin and, eventually, some uncleaved TRX-hepcidin was concentrated to 8 mgÆmL)1 Fractions (1.5 mL) of the concentrated protein solution were injected onto a BioBasic C18 semi preparative HPLC column (250 mm· 10 mm, 300 A˚; Thermo, Courtabeuf, France) under the control of a Spectra physics HPLC sys-tem The mobile phase run at 3 mLÆmin)1consisted of the water⁄ acetonitrile gradient: 100% H2O [trifluroacetic acid (TFA) 0.1%] for 10 min, 0–40% CH3CN (TFA 0.1%) for
20 min, 40–60% CH3CN (TFA 0.1%) for 20 min and 60– 100% CH3CN (TFA 0.1%) for 20 min The S-tag-hepcidin containing fractions were eluted around 60% H2O (TFA
Trang 90.1%) and 40% CH3CN (TFA 0.1%) and lyophilized using
an Alpha 1-LU Lyophilizer (Avantec, Illkirch, France)
S-hepcidin cleavage
S-hepcidin was solubilized at 1 mgÆmL)1 of protein in
20 mm Tris buffer (pH 6.7) containing 75 mm NaCl, 2 mm
CaCl2and 0.05% Chaps and digested for 6 h at room
tem-perature with 10 units of Enterokinase (Novagen) per mg
of S-hepcidin Enterokinase was removed using the
manu-facturer capture beads and the enterokinase free digestion
mixture was diluted in one volume of H2O to decrease the
ionic strength prior to injection onto a UnoQ column
(Rad) anion exchange column under the control of a
Bio-logic (Bio-Rad) device equipped with a 258 nm detector
A salt gradient was performed between 20 mm Tris buffer
at pH 7 and 20 mm Tris buffer at pH 7 containing 1 m
NaCl for human hepcidin and at pH 6.2 for the mouse
form The cleaved recombinant hepcidin, either mouse or
human, was eluted in the void volume The pure hepcidins
were further characterized by HPLC on a Vydac C18
(250 mm· 4.6 mm, 300 A˚ pores; Grace, Templemars,
France) reverse phase column Fifty microlitres of hepcidin
(0.1 mgÆmL)1) were eluted with the following gradient at
1 mLÆmin)1 from 90% of (H2O, 0.1% TFA) and 10% of
(H2O 30%, CH3CN 70%, TFA 0.1%) to 10% of (H2O,
0.1% TFA) and 90% of (H2O 30%, CH3CN 70%, TFA
0.1%) for 30 min M1hepc was eluted at 18 min 20 s and
huhepc at 18 min 45 s
Protein characterization
Protein concentration was determined using Bradford
(Bio-Rad) reagent [39]; for peptide concentration determination,
Bacitracin (1423 Da) was used as a standard rather than
serum albumin Hepcidin concentration was determined
either by weighing a salt-free lyophilized powder or using
absorbance spectroscopy (A214to A225), as described
previ-ously [2] Purification was followed using SDS⁄ PAGE
anal-ysis of peptides and small proteins (< 10 kDa) were run on
Criterion 12% BISTRIS XT gels (Bio-Rad) at 200 V and
190 mA for 45 min in MES buffer at pH 7 in the presence
or absence of the reducing agent
tris(2-carboxyethyl)phos-phine Immediately after migration, gels were treated with
glutaraldehyde (5%, v⁄ v final) for 20 min and stained using
colloidal Blue [40] Proteins (> 10 kDa) were characterized
using Capillary Electrophoresis Experion PRO260 chips
run on an Experion automated electrophoresis station
(Bio-Rad) Free thiol determination was performed
follow-ing the Ellman methodology [34] The titration curve was
performed using glutathione (4–200 lm) as a standard and
measuring absorbance (A380 to A480) on a Uvikon 420
(Kontron, Zurich, Switzerland) spectrophotometer in the
presence of 5 mm 5,5¢-dithiobis(2-nitrobenzoic acid) Free
thiol concentration was measured on hepcidin samples
using at least 20 lm solutions Mass spectrometry was run
on a LCQ advantage ion trap (Thermo Finnigan, Courta-beuf, France) mass spectrometer under an ESI positive mode (capillary at 275C, capillary voltage 21 V, spray
5 kV) SELDI-TOF MS was performed by Photeomics (Noisy le Grand, France) on a PBS IIc ProteinChip Reader (Ciphergen Bioystems Inc., Le Raincy, France) using eight-spot NP20 ProteinChips (Bio-Rad)
Cell culture and western blot analysis
The mouse monocyte-macrophage cell line J774 was cul-tured as described previously [20] To increase ferroportin distribution to the cell membrane prior to hepcidin treat-ment, cells were incubated for 16 h with Fe-nitrilotriacetate solution (Fe-NTA; FeCl3100 lm-NTA 400 lm) Synthetic human hepcidin (Peptides International), m1hepc and huhepc were used at 700 nm for 5 h as described Protein extraction and ferroportin detection were performed as previously described [20]
Acknowledgements
We would to thank Dr Dan Qing Lou for the murine cDNA prohepcidin construct and Nicole Kubat for critically reading the manuscript This study was sup-ported by funding from ANR (RO06024KK project) and EEC Framework 6 (LSHM-CT-037296 Euro-Iron1)
References
1 Krause A, Neitz S, Magert HJ, Schulz A, Forssmann
WG, Schulz-Knappe P & Adermann K (2000) LEAP-1,
a novel highly disulfide-bonded human peptide, exhibits antimicrobial activity FEBS Lett 480, 147–150
2 Park CH, Valore EV, Waring AJ & Ganz T (2001) Hepcidin, a urinary antimicrobial peptide synthesized in the liver J Biol Chem 276, 7806–7810
3 Nicolas G, Bennoun M, Porteu A, Mativet S, Beau-mont C, Grandchamp B, Sirito M, Sawadogo M, Kahn
A & Vaulont S (2002) Severe iron deficiency anemia in transgenic mice expressing liver hepcidin Proc Natl Acad Sci USA 99, 4596–4601
4 Ganz T (2003) Hepcidin, a key regulator of iron metab-olism and mediator of anemia of inflammation Blood
102, 783–788
5 Pigeon C, Ilyin G, Courselaud B, Leroyer P, Turlin B, Brissot P & Loreal O (2001) A new mouse liver-specific gene, encoding a protein homologous to human antimi-crobial peptide hepcidin, is overexpressed during iron overload J Biol Chem 276, 7811–7819
6 Zhang AS, Xiong S, Tsukamoto H & Enns CA (2004) Localization of iron metabolism-related mRNAs in rat
Trang 10liver indicate that HFE is expressed predominantly in
hepatocytes Blood 103, 1509–1514
7 Sang Y, Ramanathan B, Minton JE, Ross CR &
Blecha F (2006) Porcine liver-expressed antimicrobial
peptides, hepcidin and LEAP-2: cloning and induction
by bacterial infection Dev Comp Immunol 30, 357–
366
8 Fry MM, Liggett JL & Baek SJ (2004) Molecular
clon-ing and expression of canine hepcidin Vet Clin Pathol
33, 223–227
9 Huang PH, Chen JY & Kuo CM (2007) Three different
hepcidins from tilapia, Oreochromis mossambicus:
ana-lysis of their expressions and biological functions Mol
Immunol 44, 1922–1934
10 Lauth X, Babon JJ, Stannard JA, Singh S, Nizet V,
Carlberg JM, Ostland VE, Pennington MW, Norton
RS & Westerman ME (2005) Bass hepcidin synthesis,
solution structure, antimicrobial activities and
syner-gism, and in vivo hepatic response to bacterial
infec-tions J Biol Chem 280, 9272–9282
11 Park KC, Osborne JA, Tsoi SC, Brown LL & Johnson
SC (2005) Expressed sequence tags analysis of Atlantic
halibut (Hippoglossus hippoglossus) liver, kidney and
spleen tissues following vaccination against Vibrio
anguillarumand Aeromonas salmonicida Fish Shellfish
Immunol 18, 393–415
12 Nicolas G, Chauvet C, Viatte L, Danan JL, Bigard X,
Devaux I, Beaumont C, Kahn A & Vaulont S (2002)
The gene encoding the iron regulatory peptide hepcidin
is regulated by anemia, hypoxia, and inflammation
J Clin Invest 110, 1037–1044
13 Ganz T (2006) Hepcidin and its role in regulating
sys-temic iron metabolism Hematology Am Soc Hematol
Educ Program 1, 29–35
14 Finberg KE, Heeney MM, Campagna DR, Aydinok Y,
Pearson HA, Hartman KR, Mayo MM, Samuel SM,
Strouse JJ, Markianos K et al (2008) Mutations in
TMPRSS6 cause iron-refractory iron deficiency anemia
(IRIDA) Nat Genet 40, 569–571
15 Valore EV & Ganz T (2008) Posttranslational
process-ing of hepcidin in human hepatocytes is mediated by
the prohormone convertase furin Blood Cells Mol Dis
40, 132–138
16 Hunter HN, Fulton DB, Ganz T & Vogel HJ (2002)
The solution structure of human hepcidin, a peptide
hormone with antimicrobial activity that is involved in
iron uptake and hereditary hemochromatosis J Biol
Chem 277, 37597–37603
17 Nemeth E, Preza GC, Jung CL, Kaplan J, Waring AJ
& Ganz T (2006) The N-terminus of hepcidin is
essen-tial for its interaction with ferroportin: structure–
function study Blood 107, 328–333
18 Nicolas G, Bennoun M, Devaux I, Beaumont C,
Grandchamp B, Kahn A & Vaulont S (2001) Lack of
hepcidin gene expression and severe tissue iron overload
in upstream stimulatory factor 2 (USF2) knockout mice Proc Natl Acad Sci USA 98, 8780–8785
19 Donovan A, Lima CA, Pinkus JL, Pinkus GS, Zon LI, Robine S & Andrews NC (2005) The iron exporter ferroportin⁄ Slc40a1 is essential for iron homeostasis Cell Metab 1, 191–200
20 Delaby C, Pilard N, Goncalves AS, Beaumont C & Canonne-Hergaux F (2005) Presence of the iron exporter ferroportin at the plasma membrane of macrophages is enhanced by iron loading and down-regulated by hepcidin Blood 106, 3979–3984
21 Nemeth E, Tuttle MS, Powelson J, Vaughn MB, Dono-van A, Ward DM, Ganz T & Kaplan J (2004) Hepcidin regulates cellular iron efflux by binding to ferroportin and inducing its internalization Science 306, 2090–2093
22 Ganz T (2006) Hepcidin – a peptide hormone at the interface of innate immunity and iron metabolism Curr Top Microbiol Immunol 306, 183–198
23 Kluver E, Schulz A, Forssmann WG & Adermann K (2002) Chemical synthesis of beta-defensins and
LEAP-1⁄ hepcidin J Pept Res 59, 241–248
24 Murphy AT, Witcher DR, Luan P & Wroblewski VJ (2007) Quantitation of hepcidin from human and mouse serum using liquid chromatography tandem mass spec-trometry Blood 110, 1048–1054
25 Achmuller C, Kaar W, Ahrer K, Wechner P, Hahn R, Werther F, Schmidinger H, Cserjan-Puschmann M, Clementschitsch F, Striedner G et al (2007) N(pro) fusion technology to produce proteins with authentic
N termini in E coli Nat Methods 4, 1037–1043
26 Gerardi G, Biasiotto G, Santambrogio P, Zanella I, Ingrassia R, Corrado M, Cavadini P, Derosas M, Levi
S & Arosio P (2005) Recombinant human hepcidin expressed in Escherichia coli isolates as an iron contain-ing protein Blood Cells Mol Dis 35, 177–181
27 Wallace DF, Jones MD, Pedersen P, Rivas L, Sly LI & Subramaniam VN (2006) Purification and partial char-acterisation of recombinant human hepcidin Biochimie
88, 31–37
28 Zhang H, Yuan Q, Zhu Y & Ma R (2005) Expression and preparation of recombinant hepcidin in Escherichia coli Protein Expr Purif 41, 409–416
29 Koliaraki V, Marinou M, Samiotaki M, Panayotou G, Pantopoulos K & Mamalaki A (2008) Iron regulatory and bactericidal properties of human recombinant hepcidin expressed in Pichia pastoris Biochimie 90, 726–735
30 Prinz WA, Aslund F, Holmgren A & Beckwith J (1997) The role of the thioredoxin and glutaredoxin pathways
in reducing protein disulfide bonds in the Escherichia colicytoplasm J Biol Chem 272, 15661–15667
31 Stewart EJ, Aslund F & Beckwith J (1998) Disulfide bond formation in the Escherichia coli cytoplasm: an in vivo role reversal for the thioredoxins EMBO J 17, 5543–5550